Few months later, a TT drug called Vemurafenib (a BRAF inhibitor, BRAFi) also demonstrated clinical benefits for melanoma patients having an actionable BRAF V600E/K mutation and it rapidly became standard of care for these patients, which represent about half of all metastatic melanomas (8–11). The gene discussed is BRAF; the disease is metastatic melanoma.